The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis

Abstract

Background: Adjuvant chemotherapy is still the standard treatment for stage III-N2 nonsmall cell lung cancer after R0 resection, and it is still controversial whether conventional adjuvant radiotherapy is needed. We used meta-analysis to try to answer whether adjuvant postoperative chemoradiotherapy (POCRT) can bring survival benefits to patients with stage III-N2 nonsmall cell lung cancer after R0 resection.Methods: Up to June 25, 2021, the databases of PubMed, Embase, Cochrane Library, CNKI, and Wanfang were searched, and clinical studies on POCRT for stage III-N2 nonsmall cell lung cancer were included. RevMan5.4 software was used for meta-analysis.Results: A total of 8959 patients were included in 5 randomized controlled trials and 17 retrospective studies. The results of the meta-analysis showed that POCRT could improve 3 and 5 years overall survival (OS) rate (OR = 1.52, 95%CI: 1.05-2.20; OR = 1.30, 95%CI: 1.16-1.46), 3 and 5 years disease-free survival (DFS) rate (OR = 1.34, 95%CI: 1.01-1.76; OR = 1.74, 95%CI: 1.43-2.12), and 5-year locoregional recurrence-free survival (LRFS) rate (OR = 2.69, 95%CI: 1.76-4.11) in patients with stage III-N2 nonsmall cell lung cancer compared with adjuvant postoperative chemotherapy (POCT) alone. But could not improve 5-year distant metastasis-free survival (DMFS) rate (OR = 1.14, 95%CI: 0.52-2.52). The results of subgroup analysis showed that postoperative sequential chemoradiotherapy could improve the 3 and 5 years OS rate (OR = 2.06, 95%CI: 1.22-3.46; OR = 1.39, 95%CI: 1.21-1.59). Three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) can improve the 3 and 5 years OS rate (OR = 1.80, 95%CI: 1.09-2.99; OR = 1.31, 95%CI: 1.04-1.66). In addition, POCRT could improve the 3-year OS rate (OR = 1.88, 95%CI: 1.21-2.92) in patients with N2 single-station lymph node metastasis compared with POCT alone. Conclusion:Compared with POCT alone, adjuvant POCRT can significantly improve the overall survival rate of patients with NSCLC after R0 resection of stage III-N2, especially in patients with N2 single-station lymph node metastasis. Accurate radiotherapy techniques such as 3DCRT or IMRT are recommended, and postoperative sequential chemoradiotherapy is the best treatment mode.

Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments

“…Surgery is the foremost curative treatment for patients with resectable NSCLC. 2 Yet, the recurrence rates post‐resection remain high at 30%–50%, 3 , 4 , 5 with median time from surgery to local recurrence of ~14 months and median time to distant recurrence of 12.5 months. 5 , 6 In patients with unresectable NSCLC, definitive radiotherapy or concurrent definitive chemoradiotherapy (CRT) are the preferred treatment choices.…”

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials

“…[1][2][3] More than 70% of the patients are advanced at the time of diagnosis and cannot undergo radical surgery. [4] For a long time, the treatment of advanced NSCLC is mainly based on standard platinum-containing dualdrug chemotherapy, but its effective rate is only 25% to 35%, the median survival time is 8 to 10 months, and the 1-year survival rate is less than 40%. [5,6] In recent years, the development and application of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) have brought hope for the treatment of NSCLC at the bottleneck stage.…”

Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs

“…[ 1 ] More than 80% of all lung cancer patients are non-small cell lung cancer (NSCLC). [ 2 , 3 ] As the early clinical symptoms of lung cancer are not obvious and the disease progresses rapidly, most patients are diagnosed in an advanced stage and lose the best opportunity for surgical treatment. For a long time in the past, advanced NSCLC patients mainly rely on chemotherapy to prolong overall survival.…”